JP2011506469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506469A5 JP2011506469A5 JP2010538165A JP2010538165A JP2011506469A5 JP 2011506469 A5 JP2011506469 A5 JP 2011506469A5 JP 2010538165 A JP2010538165 A JP 2010538165A JP 2010538165 A JP2010538165 A JP 2010538165A JP 2011506469 A5 JP2011506469 A5 JP 2011506469A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- group
- alkyloxy
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, amino Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 9
- 239000000460 chlorine Substances 0.000 claims 8
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 201000001431 Hyperuricemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 2
- 125000006576 di-(C1-C3-alkyl)-aminocarbonyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- OJNWITIERBFDHJ-RBMZQIMRSA-N (1r,2r,3s,4r,5r,6s)-4-[4-chloro-3-[(4-cyclohexylphenyl)methyl]phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3,5-tetrol Chemical compound O[C@H]1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1C1=CC=C(Cl)C(CC=2C=CC(=CC=2)C2CCCCC2)=C1 OJNWITIERBFDHJ-RBMZQIMRSA-N 0.000 claims 1
- ISQIDKPLOKBKHJ-AIURUUSXSA-N (1r,2r,3s,4r,5r,6s)-4-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3,5-tetrol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@H]2[C@H]([C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O)=CC=C1Cl ISQIDKPLOKBKHJ-AIURUUSXSA-N 0.000 claims 1
- XYZUMOZQVNKWQE-AIURUUSXSA-N (1r,2r,3s,4r,5r,6s)-4-[4-chloro-3-[(4-ethylphenyl)methyl]phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3,5-tetrol Chemical compound C1=CC(CC)=CC=C1CC1=CC([C@@H]2[C@H]([C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O)=CC=C1Cl XYZUMOZQVNKWQE-AIURUUSXSA-N 0.000 claims 1
- HOAFNCIYHHMECH-SCTSWAKVSA-N (1r,2r,3s,4r,5r,6s)-4-[4-chloro-3-[(4-propylphenyl)methyl]phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3,5-tetrol Chemical compound C1=CC(CCC)=CC=C1CC1=CC([C@@H]2[C@H]([C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O)=CC=C1Cl HOAFNCIYHHMECH-SCTSWAKVSA-N 0.000 claims 1
- OKFBOLRSXHCDET-GKZPLSAOSA-N (1r,2r,3s,4r,5r,6s)-4-[4-chloro-3-[[4-(1-hydroxyethyl)phenyl]methyl]phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3,5-tetrol Chemical compound C1=CC(C(O)C)=CC=C1CC1=CC([C@@H]2[C@H]([C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O)=CC=C1Cl OKFBOLRSXHCDET-GKZPLSAOSA-N 0.000 claims 1
- UWNNGHCXCMEVKY-LCNLMQJVSA-N (1r,2r,3s,4s,6r)-4-[4-chloro-3-[(4-ethylphenyl)methyl]phenyl]-6-(hydroxymethyl)-5-methylidenecyclohexane-1,2,3-triol Chemical compound C1=CC(CC)=CC=C1CC1=CC([C@@H]2C([C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)=C)=CC=C1Cl UWNNGHCXCMEVKY-LCNLMQJVSA-N 0.000 claims 1
- XTXXXHYCYNHHAW-SROFAIGKSA-N (1r,2s,3r,4r,5s,6r)-4-[2-[(4-ethylphenyl)methyl]phenoxy]-6-(hydroxymethyl)cyclohexane-1,2,3,5-tetrol Chemical compound C1=CC(CC)=CC=C1CC1=CC=CC=C1O[C@@H]1[C@@H](O)[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XTXXXHYCYNHHAW-SROFAIGKSA-N 0.000 claims 1
- ZOECHXYUVRRUJW-GMISPTPDSA-N (4r,5r,6r,7s,8s)-8-[4-chloro-3-[(4-ethylphenyl)methyl]phenyl]-4-(hydroxymethyl)spiro[2.5]octane-5,6,7-triol Chemical compound C1=CC(CC)=CC=C1CC1=CC([C@@H]2C3(CC3)[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)=CC=C1Cl ZOECHXYUVRRUJW-GMISPTPDSA-N 0.000 claims 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- DYKFSNIGUCSCGO-AIURUUSXSA-N 1-[4-[[2-chloro-5-[(1r,2s,3r,4r,5s,6r)-2,3,4,6-tetrahydroxy-5-(hydroxymethyl)cyclohexyl]phenyl]methyl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1CC1=CC([C@@H]2[C@H]([C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O)=CC=C1Cl DYKFSNIGUCSCGO-AIURUUSXSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000005171 cycloalkylsulfanyl group Chemical group 0.000 claims 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 1
- 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims 1
- 150000002440 hydroxy compounds Chemical class 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940116269 uric acid Drugs 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1351707P | 2007-12-13 | 2007-12-13 | |
| US61/013,517 | 2007-12-13 | ||
| PCT/US2008/086472 WO2009076550A1 (en) | 2007-12-13 | 2008-12-11 | Benzylphenyl cyclohexane derivatives and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506469A JP2011506469A (ja) | 2011-03-03 |
| JP2011506469A5 true JP2011506469A5 (cg-RX-API-DMAC10.html) | 2012-02-02 |
| JP5507464B2 JP5507464B2 (ja) | 2014-05-28 |
Family
ID=40754059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538165A Expired - Fee Related JP5507464B2 (ja) | 2007-12-13 | 2008-12-11 | ベンジルフェニルシクロヘキサン誘導体およびその使用方法 |
Country Status (16)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0916769A2 (pt) | 2008-07-15 | 2017-09-26 | Theracos Inc | derivados de benzilbenzeno deuterados e métodos de uso |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| MX2013013734A (es) * | 2011-05-26 | 2014-02-27 | Tfchem | Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo. |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103570671B (zh) * | 2012-09-26 | 2016-03-30 | 上海天慈生物谷生物工程有限公司 | 一种降糖化合物及其制法和应用 |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| WO2015091313A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
| US10759729B2 (en) * | 2016-11-07 | 2020-09-01 | The Chinese University Of Hong Kong | Compounds for treating diabetes |
| CN116785268A (zh) * | 2022-03-14 | 2023-09-22 | 江苏万邦生化医药集团有限责任公司 | 一种sglt-2抑制剂的药物组合物 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL122835B1 (en) * | 1977-09-13 | 1982-08-31 | Process for preparing novel cycloalkanols | |
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| WO1994011030A1 (en) | 1992-11-13 | 1994-05-26 | The Ohio State University Research Foundation | C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
| WO1998031697A1 (en) | 1997-01-15 | 1998-07-23 | Sankyo Company, Limited | Aryl c-glycoside compounds and sulfated esters thereof |
| US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
| US7407978B2 (en) | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| CA2429426A1 (en) | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
| TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| JP2004536047A (ja) | 2001-04-11 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法 |
| US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
| DE60332743D1 (de) | 2002-08-08 | 2010-07-08 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
| WO2004014931A1 (ja) | 2002-08-09 | 2004-02-19 | Taisho Pharmaceutical Co., Ltd. | アリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| DE10258008B4 (de) | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10258007B4 (de) | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| BR0317929A (pt) | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
| KR101001848B1 (ko) | 2003-03-14 | 2010-12-17 | 고토부키 세이야쿠 가부시키가이샤 | Ｃ-글리코시드 유도체 또는 이의 염, 및 이를 포함하는 의약 조성물 |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| WO2005012318A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
| CN103214471B (zh) | 2003-08-01 | 2018-02-06 | 田边三菱制药株式会社 | 具有钠依赖型葡萄糖转运体抑制活性的化合物的制备方法 |
| EP1679966A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED BENZIMIDAZOLE, BENZOTRIAZOL AND BENZIMIDAZOLON-O-GLUCOSIDES |
| ATE422204T1 (de) | 2003-08-26 | 2009-02-15 | Boehringer Ingelheim Int | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US7375090B2 (en) | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
| DE10361133A1 (de) | 2003-12-22 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7371732B2 (en) | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
| WO2005085237A1 (ja) | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| IL218714A (en) | 2004-03-16 | 2013-02-28 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| EP1731524A4 (en) | 2004-03-31 | 2009-05-20 | Kissei Pharmaceutical | PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| CN101010276B (zh) * | 2004-07-26 | 2011-01-12 | 中外制药株式会社 | 环己烷衍生物、其前体药物及其盐、以及含有它的糖尿病治疗药 |
| TW200606129A (en) * | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| CA2574451A1 (en) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| MX2007003785A (es) | 2004-09-29 | 2007-07-12 | Kissei Pharmaceutical | Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo. |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| TW200635599A (en) | 2004-12-16 | 2006-10-16 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TW200637839A (en) | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| DE602006009772D1 (de) | 2005-02-23 | 2009-11-26 | Boehringer Ingelheim Int | Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2) |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| CA2605245A1 (en) | 2005-04-15 | 2006-10-19 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7772191B2 (en) * | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| EP1910390B1 (en) | 2005-07-27 | 2010-05-19 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
| GB0516156D0 (en) * | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
| ATE484499T1 (de) | 2005-08-30 | 2010-10-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| AU2006289093A1 (en) | 2005-09-08 | 2007-03-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| RU2437876C2 (ru) | 2006-05-19 | 2011-12-27 | Тайсо Фармасьютикал Ко., Лтд. | Соединение с-фенилглицитола для лечения диабета |
| JP5230613B2 (ja) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| RU2492175C2 (ru) | 2007-04-02 | 2013-09-10 | Теракос, Инк. | Бензиловые производные гликозидов и способы их применения |
| NO2187742T3 (cg-RX-API-DMAC10.html) | 2007-08-23 | 2018-03-24 |
-
2008
- 2008-11-12 UA UAA201008620A patent/UA101004C2/uk unknown
- 2008-12-11 BR BRPI0819930A patent/BRPI0819930A2/pt not_active IP Right Cessation
- 2008-12-11 KR KR1020107015420A patent/KR101567969B1/ko not_active Expired - Fee Related
- 2008-12-11 WO PCT/US2008/086472 patent/WO2009076550A1/en not_active Ceased
- 2008-12-11 AU AU2008335080A patent/AU2008335080B2/en not_active Ceased
- 2008-12-11 NZ NZ586639A patent/NZ586639A/en not_active IP Right Cessation
- 2008-12-11 EP EP08859426.2A patent/EP2230907B1/en active Active
- 2008-12-11 CA CA2707909A patent/CA2707909C/en not_active Expired - Fee Related
- 2008-12-11 US US12/333,190 patent/US8129434B2/en not_active Expired - Fee Related
- 2008-12-11 TW TW097148259A patent/TWI426081B/zh not_active IP Right Cessation
- 2008-12-11 RU RU2010128940/04A patent/RU2505521C2/ru not_active IP Right Cessation
- 2008-12-11 JP JP2010538165A patent/JP5507464B2/ja not_active Expired - Fee Related
- 2008-12-11 CN CN200880126441.9A patent/CN101938902B/zh not_active Expired - Fee Related
- 2008-12-12 AR ARP080105417A patent/AR071268A1/es not_active Application Discontinuation
-
2010
- 2010-06-07 IL IL206234A patent/IL206234A0/en unknown
- 2010-06-22 ZA ZA2010/04400A patent/ZA201004400B/en unknown
-
2018
- 2018-02-21 AR ARP180100403A patent/AR113211A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506469A5 (cg-RX-API-DMAC10.html) | ||
| RU2497526C2 (ru) | Производные бензилбензола и способы их применения | |
| RU2010128940A (ru) | Производные бензилфенилциклогексана и способы их применения | |
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| JP6968181B2 (ja) | インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| DK2888239T3 (en) | REDUCED CENTRAL CORCHET THICKENING USING HYDROFILE ESTER PRODUGS OF BETA-CHLORCYCLOPENTANE | |
| JP5275975B2 (ja) | 高脂血症の予防及び／又は治療剤 | |
| JP2010529203A5 (cg-RX-API-DMAC10.html) | ||
| JP2010516700A5 (cg-RX-API-DMAC10.html) | ||
| JP2008539267A5 (cg-RX-API-DMAC10.html) | ||
| JP2010523476A5 (cg-RX-API-DMAC10.html) | ||
| JP2010514758A5 (cg-RX-API-DMAC10.html) | ||
| US20220162173A1 (en) | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment | |
| JP2014518853A5 (cg-RX-API-DMAC10.html) | ||
| JP2008539268A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2014050134A1 (ja) | 脂質異常症治療剤 | |
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| CN101056633A (zh) | 用于贫血治疗的PI3激酶γ抑制剂 | |
| RU2006138426A (ru) | Производные тиазолопиридина, содержащие их фармацевтические композиции и способы лечения состояний, опосредованных глюкокиназой | |
| JP2020520949A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2020234275A5 (cg-RX-API-DMAC10.html) | ||
| JP2008530242A5 (cg-RX-API-DMAC10.html) | ||
| JP2010513489A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2021071837A5 (cg-RX-API-DMAC10.html) | ||
| WO2020128614A9 (en) | Method for treating interstital lung disease |